LOGIN  |  REGISTER
Recursion
Compass Therapeutics

PacBio to Report First Quarter 2023 Financial Results on May 2, 2023

April 18, 2023 | Last Trade: US$1.86 0.08 -3.89

MENLO PARK, Calif., April 18, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2023 financial results on Tuesday, May 2, 2023, at 4:30 pm Eastern Time.

The call will be webcast and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/.

Date: Tuesday, May 2, 2023 at 4:30 pm ET (1:30 pm PT)
Listen live via internet or replay: https://investor.pacificbiosciences.com/ 
Toll-free: 1-888-349-0136 
International: 1-412-317-6011

If using the dial-in option, please dial into the call five to ten minutes prior to start time using the appropriate number above and ask to join the "PacBio Q1 Earnings Call."

About PacBio

Pacific Biosciences of California, Inc. is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems.  Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our existing HiFi long read sequencing and our emerging SBB® short read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information please visit www.pacb.com and follow @PacBio.

Contacts

Investors:
Todd Friedman
650.521.8450
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media:
Lizelda Lopez
This email address is being protected from spambots. You need JavaScript enabled to view it.

Recursion

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB